The case against Goldman

The Securities and Exchange Commission charged Goldman with failing to disclose a conflict of interest when it sold a complex financial security called Abacus.

The powerhouse Wall Street investment bank Goldman Sachs this week vowed an aggressive defense of fraud charges filed by the Securities and Exchange Commission, but the firm faced continued fallout from the allegations. The SEC last week charged Goldman with failing to disclose a conflict of interest when it sold a complex financial security, called Abacus. Abacus was created for hedge fund manager John Paulson, who had specifically requested that Goldman create a package of low-quality mortgages that he could “short,” or bet against—in effect designing the security to fail. Paulson made $1 billion when the value of Abacus plunged, while U.S., British, and German financial firms lost hundreds of millions of dollars. The SEC reportedly voted 3–2 along party lines to charge Goldman, after months of secret negotiations failed to produce a settlement.

Goldman had “every incentive to play fast and loose,” said Andrew Leonard in Salon.com. As Washington retreated from regulating the financial industry, firms behaved in “ever more reckless and greedy ways.” In this anything-goes environment, Goldman apparently thought that there was nothing morally or legally wrong with selling toxic products that were designed to fail. Now that the SEC has “brought the hammer down,” perhaps Wall Street will finally clean up its act.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us